Oral Testosterone Undecanoate Shows No Liver Harm Over Two Years

Estimated reading time: 8 minutes

Key takeaways

Two-year follow-up of oral testosterone undecanoate (TU; Jatenzo) in hypogonadal men showed no clinically meaningful liver toxicity and stable liver function tests.
Safety signals (PSA, hematocrit, HDL reduction, and modest blood pressure rise) were consistent with other TRT options like injections and gels.
TU is absorbed via the lymphatic system, avoiding first-pass hepatic metabolism that contributed to liver risks with older oral androgens.
Evidence is reassuring but limited by open-label design, small sample size (n=86 at 2 years), and follow-up capped at two years.
Monitoring for hematocrit, PSA, blood pressure, and lipids remains standard for men on any TRT regimen.

Why “Oral Testosterone” Once Meant Liver Worries
What Is Oral Testosterone Undecanoate (Jatenzo) and How It Differs
The 2-Year Safety Data at a Glance
What This Means for “Oral TRT Liver Damage”
Other Safety Considerations: What to Watch
Practical Implications for Patients Considering Jatenzo
Limitations of the Evidence and Open Questions
How Oral TU Fits Among TRT Options
Conclusion

Oral TU Liver Safety: 2-Year Data Confirms No Hepatotoxicity vs Older Forms

Oral testosterone therapy has long carried a stigma around liver risk, largely due to experiences with older formulations. The recent 2-year data on oral testosterone undecanoate (TU; brand name Jatenzo) offers a very different picture: maintenance of normal testosterone levels with no evidence of hepatotoxicity in hypogonadal men. Below we break down what changed, what the evidence shows, and what it means if you’re weighing oral TRT against injections or gels.

Why “Oral Testosterone” Once Meant Liver Worries

For years, “oral testosterone” was practically synonymous with “liver risk.” That reputation was earned by alkylated oral androgens such as methyltestosterone, which were historically linked to hepatotoxicity. Those older molecules undergo significant first-pass metabolism in the liver and have been associated with adverse hepatic outcomes.

Oral testosterone undecanoate (TU) is a fundamentally different approach. Rather than pushing a molecule through the liver to achieve active levels, TU leverages lymphatic absorption to bypass first-pass hepatic metabolism. The clinical question has been whether this mechanism translates into real-world liver safety. Two-year data now provide a more confident answer.

What Is Oral Testosterone Undecanoate (Jatenzo) and How It Differs

FDA timeline: Jatenzo (oral TU) received FDA approval in March 2019 and became commercially available in early 2020.
Absorption: TU is delivered as an ester that is preferentially absorbed via the intestinal lymphatic system, aiming to reduce first-pass liver exposure.
Clinical positioning: It offers a needle-free option that avoids the transfer risk of gels. For many men who dislike injections or find transdermal adherence challenging, oral TU provides a practical alternative.

Importantly for men worried about oral TRT liver damage, the clinical trials and the two-year extension study did not show clinically meaningful changes in liver function tests (LFTs).

The 2-Year Safety Data at a Glance

A 2-year open-label extension followed 86 hypogonadal men who continued on oral TU after an initial year of therapy. The results are notable for both efficacy and safety:

Testosterone levels: Men maintained eugonadal (normal) serum testosterone throughout the study period.
Liver function: No clinically significant changes were observed in ALT, AST, alkaline phosphatase, or bilirubin over the 2-year period. One participant had a transient ALT elevation to more than 4 times the upper limit of normal around Day 270, which normalized by Day 290 without ongoing liver issues.
Prostate and hematologic signals: Small, statistically significant increases in prostate-specific antigen (PSA) and hematocrit were observed—changes consistent with what’s seen across injectable and transdermal TRT.
Lipids and blood pressure: Minimal LDL impact was reported, with a decrease in HDL cholesterol that is typical of TRT. Average systolic blood pressure rose modestly (on the order of a few millimeters of mercury).
Overall: The safety profile of oral TU tracked closely with non-oral TRT options and did not show the hepatotoxicity historically associated with older oral androgens.

These findings echo earlier trial data showing stable LFTs with oral TU and support the idea that TU’s lymphatic absorption avoids the liver strain that prompted concern with prior oral agents.

What This Means for “Oral TRT Liver Damage”

If you’re searching “oral TRT liver damage,” you’re likely trying to separate past concerns from current options. The key takeaway is that oral TU (Jatenzo) does not behave like older alkylated oral androgens with respect to the liver. Over two years of follow-up in hypogonadal men:

No signal of clinically meaningful hepatotoxicity was seen.
Routine lab monitoring did not show problematic trends in liver enzymes or bilirubin.
A single, short-lived ALT spike did not translate to broader safety concerns.

While any medication can affect individuals differently, the best available clinical evidence suggests that oral TU’s design—bypassing first-pass hepatic metabolism—largely decouples modern oral TRT from the historical liver damage narrative.

Other Safety Considerations: What to Watch

Oral TU’s liver profile is encouraging, but TRT monitoring remains important regardless of delivery method. The signals below are expected class effects and are reflected in oral TU data and labeling:

Hematocrit: TRT can increase red blood cell mass. Clinicians routinely track hematocrit and may adjust or pause therapy if levels become too high.
PSA and prostate health: Small increases in PSA can occur; monitoring and clinical context matter, especially for men with known prostate risks.
Blood pressure: Average systolic blood pressure increases of roughly 3–6 mmHg have been observed. Men with existing hypertension should have blood pressure routinely assessed.
Lipids: Some reduction in HDL is typical with TRT.
Indication: Like other testosterone products, oral TU is indicated for men with confirmed hypogonadism; it is not approved for age-related testosterone decline without a clear deficiency diagnosis.

These are not reasons to avoid therapy outright; they are part of the risk-benefit calculus that clinicians use to guide safe, individualized TRT.

Practical Implications for Patients Considering Jatenzo

Convenience and adherence: Oral TU offers a needle-free route and avoids gel transfer risk to partners or children. For some men, daily oral dosing improves adherence; others may prefer less frequent injection schedules.
Monitoring cadence: As with any TRT, expect baseline labs and periodic follow-up for hematocrit, PSA, lipids, and blood pressure. The 2-year data support that these parameters typically move in the same direction as with non-oral TRT.
Liver reassurance: For men specifically concerned about oral testosterone and the liver, the available two-year evidence is reassuring and materially different from experiences with older oral agents.
Individual variability: Dosing and response can vary. Maintaining eugonadal levels is the goal; clinicians may adjust dosing based on serum testosterone and side-effect profile.
Lifestyle and comorbidities: Pre-existing cardiovascular risk, sleep apnea, or prostate history may shape the choice and monitoring plan. The absence of hepatotoxicity does not eliminate broader TRT considerations.
Access and support: Coordinated care—including lab scheduling, medication management, and clear follow-up plans—helps sustain both efficacy and safety over time. At Taurus Meds, we focus on providing structured support so patients and clinicians can track progress and make informed decisions.

Limitations of the Evidence and Open Questions

The two-year data on Jatenzo are meaningful, but not definitive for all questions men might have about long-term safety:

Study design and size: The extension was open-label and industry-supported, with 86 men completing two years. While informative, it’s not a large, blinded outcomes trial.
Duration: Data beyond two years are limited. Longer follow-up will be important for understanding cardiovascular and prostate outcomes over time.
Comparative effectiveness: Head-to-head trials versus other modern TRT formulations could clarify differences in adherence, metabolic effects, and patient-reported outcomes.
Real-world use: Adherence patterns and variability in absorption outside of trial settings merit ongoing study, including how different oral TU products perform across diverse patient populations.

For now, the best reading of the evidence is that oral TU delivers the expected benefits of TRT with a safety profile consistent with non-oral options—and without the liver toxicity shadow that accompanied earlier oral androgens.

How Oral TU Fits Among TRT Options

Injections: Offer predictable testosterone exposure with dosing every 1–2 weeks (or longer with some esters). Some men prefer fewer dosing events; others dislike needles or experience peak–trough swings.
Transdermals: Avoid needles and allow daily dosing, but require skin precautions to prevent transfer and may cause local irritation.
Oral TU: Provides daily oral dosing without first-pass liver metabolism. The two-year data support its liver safety and expected TRT class effects.

The “right” option depends on confirmation of hypogonadism, personal preferences, lifestyle, tolerance, and ongoing lab and clinical findings. It’s reasonable to consider oral TU if you want a needle-free route and are reassured by the emerging liver safety profile.

Conclusion

Oral TU (Jatenzo) represents a significant shift in how we think about oral testosterone. The two-year extension data in hypogonadal men show no evidence of hepatotoxicity, with liver function remaining stable and overall safety tracking closely with injections and gels. While monitoring for hematocrit, PSA, blood pressure, and lipids remains standard, the long-standing association between “oral TRT” and liver damage does not reflect what we see with TU.

As with all TRT decisions, individualized assessment and thoughtful follow-up matter. The current evidence offers men a practical, needle-free option that appears to sidestep the liver risks of older oral androgens—an important development for patient choice and comfort.

Disclaimer

This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider about any questions you have regarding a medical condition or therapy.

Oral Testosterone Undecanoate Shows No Liver Harm Over Two Years